Portfolio News
Sofinnova MD Start
ELSAN partners with MD Start III to accelerate medtech innovation
This collaboration aims to enable ELSAN physicians to transform their ideas for innovation into clinically-validated devices and to contribute their expertise to new projects.
Related Strategy
MD StartRelated Deal lead
Anne OsdoitThis collaboration aims to enable ELSAN physicians to transform their ideas for innovation into clinically-validated devices and to contribute their expertise to new projects.
June 25, 2020 - PARIS, France -
ELSAN, a leader in the private hospital sector in France, announces a strategic partnership with the Sofinnova MD START III acceleration fund. Through this partnership, ELSAN becomes an investor in the acceleration fund co-created and managed by Sofinnova Partners, a leading European venture capital firm, and offers its healthcare practitioners the means to accelerate the development of their medical device innovations for the benefit of patients.
"We are delighted that ELSAN is joining Sofinnova MD Start III as a community of clinical investigators and experts," commented Anne Osdoit, Partner at Sofinnova Partners.
Related News
Sensorion Announces Approval of Clinical Trial Application in France for SENS-601, Its Investigational Gene Therapy for the Treatment of GJB2-Related Hearing Loss
Biotalys Secures Product Registration in California for EVOCA®, Strengthening Regulatory Pathway for Its Lead Asset EVOCA NG
Inventiva Announces Last Patient Visit in NATiV3 Phase 3 Clinical Trial of Lanifibranor in MASH
Medtronic announces strategic investment in Pi-Cardia to accelerate innovation for complex TAVR
AAVantgarde appoints Megan Zoschg Canniere as Chief Regulatory & Quality Officer